Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.

Yosuke KanoManabu OhashiNaoki HikiDaisuke TakahariKeisho ChinKensei YamaguchiYasuo TsudaYoshiaki ShojiItaru YasufukuKojiro EtoSatoshi IdaKoshi KumagaiSouya NunobeTakeshi Sano

Published in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2018)

Survival outcome shown in this study of patients treated with 1-year adjuvant S-1 after D2 gastrectomy at a high-volume cancer hospital will provide a reference for future adjuvant trials targeting JC-14/TNM-7 stage II/III disease.

Keyphrases

early stage
healthcare
papillary thyroid
current status
randomized controlled trial
emergency department
open label
squamous cell
combination therapy
squamous cell carcinoma
cancer therapy
adverse drug
drug delivery
young adults
study protocol